2026 Global: Balloon-Expandable Stents Market -Competitive Review (2032) report
Description
The 2026 Global: Balloon-Expandable Stents Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Medtronic plc, headquartered in Dublin, Ireland, is a global leader in cardiovascular devices, including balloon-expandable coronary stents used in percutaneous interventions. Its portfolio spans bare-metal and drug-eluting platforms, integrated with delivery systems that support accurate placement across complex anatomies. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, offers a broad line of balloon-expandable stents, notably in the TAXUS and Promus families, distributed through a worldwide sales and service network. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, markets the XIENCE series of drug-eluting balloon-expandable stents, a cornerstone of contemporary PCI and a focus for regulatory and post-market surveillance. Cordis, a Cardinal Health company headquartered in Dublin, Ohio, United States, maintains a diversified stent portfolio including balloon-expandable designs complemented by clinical education and hospital integration programs. Collectively, these four firms set standards for deliverability, long-term safety, and market access in core interventional territories, and influence pricing, reimbursement, and innovation.
Terumo Corporation, headquartered in Tokyo, Japan, supplies cardiovascular devices including balloon-expandable stents as part of an integrated catheter ecosystem. Its stent offerings are complemented by advanced delivery systems and compatibility with a range of imaging modalities, enabling consistent procedural success across diverse patient populations. MicroPort Scientific Corporation, based in Shanghai, China, has grown a multinational footprint with a broad portfolio of balloon-expandable stents and ancillary interventional tools, supported by local manufacturing capacity and regional distribution networks. Lifetech Scientific Corporation, headquartered in Shenzhen, China, focuses on affordable stent platforms and companion devices for emerging markets, emphasizing deliverability through braided and flexible stent designs and a robust catheter line. Meril Life Sciences, headquartered in Ahmedabad, India, has expanded its balloon-expandable stent family (notably its Myval platform) into multiple geographies, leveraging a strong Indian clinical base and growing presence in Europe and the Middle East through partnerships and direct sales channels and service.
Biosensors International Holdings, Ltd., headquartered in Singapore, is a major global player in interventional cardiovascular devices, offering balloon-expandable stents alongside drug-eluting platforms and proprietary coatings that optimize endothelial response. The company emphasizes regional manufacturing and a diversified distribution network to support adoption in Asia-Pacific, Europe, and the Americas, with a focus on training and post-procedure support to improve long-term outcomes. Nipro Corporation, headquartered in Osaka, Japan, maintains a credible presence in the balloon-expandable stent segment through its vascular devices portfolio, which includes stents and companion delivery systems designed for predictable expansion and precise deployment. Both firms contribute meaningfully to the competitive dynamics of the balloon-expandable stents market by advancing deliverability, expansion uniformity, and compatibility with next-generation imaging and physiological assessment tools. Taken together with the previously noted global players, these ten organizations drive ongoing product development, regulatory adaptation, and market access, shaping choices for clinicians and patients across high-resource settings.
Medtronic plc, headquartered in Dublin, Ireland, is a global leader in cardiovascular devices, including balloon-expandable coronary stents used in percutaneous interventions. Its portfolio spans bare-metal and drug-eluting platforms, integrated with delivery systems that support accurate placement across complex anatomies. Boston Scientific Corporation, based in Marlborough, Massachusetts, United States, offers a broad line of balloon-expandable stents, notably in the TAXUS and Promus families, distributed through a worldwide sales and service network. Abbott Laboratories, headquartered in Abbott Park, Illinois, United States, markets the XIENCE series of drug-eluting balloon-expandable stents, a cornerstone of contemporary PCI and a focus for regulatory and post-market surveillance. Cordis, a Cardinal Health company headquartered in Dublin, Ohio, United States, maintains a diversified stent portfolio including balloon-expandable designs complemented by clinical education and hospital integration programs. Collectively, these four firms set standards for deliverability, long-term safety, and market access in core interventional territories, and influence pricing, reimbursement, and innovation.
Terumo Corporation, headquartered in Tokyo, Japan, supplies cardiovascular devices including balloon-expandable stents as part of an integrated catheter ecosystem. Its stent offerings are complemented by advanced delivery systems and compatibility with a range of imaging modalities, enabling consistent procedural success across diverse patient populations. MicroPort Scientific Corporation, based in Shanghai, China, has grown a multinational footprint with a broad portfolio of balloon-expandable stents and ancillary interventional tools, supported by local manufacturing capacity and regional distribution networks. Lifetech Scientific Corporation, headquartered in Shenzhen, China, focuses on affordable stent platforms and companion devices for emerging markets, emphasizing deliverability through braided and flexible stent designs and a robust catheter line. Meril Life Sciences, headquartered in Ahmedabad, India, has expanded its balloon-expandable stent family (notably its Myval platform) into multiple geographies, leveraging a strong Indian clinical base and growing presence in Europe and the Middle East through partnerships and direct sales channels and service.
Biosensors International Holdings, Ltd., headquartered in Singapore, is a major global player in interventional cardiovascular devices, offering balloon-expandable stents alongside drug-eluting platforms and proprietary coatings that optimize endothelial response. The company emphasizes regional manufacturing and a diversified distribution network to support adoption in Asia-Pacific, Europe, and the Americas, with a focus on training and post-procedure support to improve long-term outcomes. Nipro Corporation, headquartered in Osaka, Japan, maintains a credible presence in the balloon-expandable stent segment through its vascular devices portfolio, which includes stents and companion delivery systems designed for predictable expansion and precise deployment. Both firms contribute meaningfully to the competitive dynamics of the balloon-expandable stents market by advancing deliverability, expansion uniformity, and compatibility with next-generation imaging and physiological assessment tools. Taken together with the previously noted global players, these ten organizations drive ongoing product development, regulatory adaptation, and market access, shaping choices for clinicians and patients across high-resource settings.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
